KORU Medical Systems Inc

KORU Medical Systems Inc(KRMD)股票分析

$3.300

+0.072 (+2.17%)收盤時

Loading chart…
High
3.315
Open
3.200
VWAP
3.27
Vol
172.88K
Mkt Cap
130.43M
Low
3.200
Amount
565.61K
EV/EBITDA, TTM
38.54

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

AI analysis of KORU Medical Systems Inc (KRMD)

hold

KORU Medical Systems Inc is currently priced at $3.23, which is significantly below the analyst price targets of $6 and $8, indicating potential upside. However, the stock has a low RSI of 31.63, suggesting it is oversold, but the forward P/E ratio of 188.68 indicates high valuation concerns. The company has shown revenue growth with Q2 2026 revenue at $12.05 million, but it has also reported a net income loss of $807,078 in Q1 2026. The main risk is the high forward P/E ratio, which could indicate overvaluation if growth does not materialize as expected.

估值指標

The current forward P/E ratio for KORU Medical Systems Inc (KRMD) is 188.68, compared to its 5-year average forward P/E of -11.77.

Forward P/E

Overvalued
5Y Average P/E
-11.77
Current P/E
188.68
高估
102.51
低估
-126.05

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-24.27
Current EV/EBITDA
38.54
高估
60.02
低估
-108.56

Forward P/S

Undervalued
5Y Average P/S
4.17
Current P/S
2.64
高估
5.17
低估
3.17

Alphio AI Price Scenarios for KRMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%KRMD

$3.23

情境價格

B

Base

Base · 50%KRMD

$2.98

情境價格

B

Bear

Bear · 25%KRMD

$2.84

情境價格

事件時間軸

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

Sees FY26 Gross Margin Between 61%-63%

資訊

KRMD FAQ — answered by Alphio AI

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is currently priced at $3.23, which is significantly below the analyst price targets of $6 and $8, indicating potential upside. However, the stock has a low RSI of 31.63, suggesting it is oversold, but the forward P/E ratio of 188.68 indicates high valuation concerns. The company has shown revenue growth with Q2 2026 revenue at $12.05 million, but it has also reported a net income loss of $807,078 in Q1 2026. The main risk is the high forward P/E ratio, which could indicate overvaluation if growth does not materialize as expected.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始